ScreenerHero

VERA Vera Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · veratx.com
30.25USD+2.82%Mkt Cap: 2.18B $P/E: —

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a ful…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.18B USD
Enterprise Value1.70B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-299.62M USD
Revenue/Share—
Last Price30.25 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees361
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.91
PEG—
EV/EBITDA-4.09
EV/Revenue—
P/S—
P/B5.19
EPS (TTM)-5.87
EPS (Forward)-4.26
52W Range
23.0522% of range56.05
52W High56.05 USD
52W Low23.05 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-49.56%
ROA-40.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-241.10M USD
CapEx (TTM)630.00K USD
FCF Margin—
FCF Yield-9.77%
Net Debt-422.26M USD
Net Debt/EBITDA1.02
Balance Sheet
Debt/Equity0.13
Current Ratio10.92
Quick Ratio10.41
Book Value/Sh5.67 USD
Cash/Share6.93 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)77.50 USD
Upside (mean)+156.2%
Target Range34.00 USD – 100.00 USD
34.00+156.2% to mean100.00
# Analysts14
Ownership
Shares Out.72.06M
Float52.39M
Insiders0.95%
Institutions118.09%
Short Interest
Short Ratio7.3d
Short % Float26.91%
Short % Out.23.64%
Shares Short17.04M
Short (prev mo.)16.81M
Technical
SMA 5032.97 (-8.2%)
SMA 20038.93 (-22.3%)
Beta1.05
S&P 52W Chg16.45%
Avg Vol (30d)2.15M
Avg Vol (10d)1.70M
Technical Indicators
RSI (14)39.5
MACD-1.0577
MACD Signal-0.6584
MACD Hist.-0.3994
BB Upper36.89 USD
BB Middle32.93 USD
BB Lower28.97 USD
BB Width24.04%
ATR (14)1.819 USD
Vol Ratio (20d)1.67x